Anne Searls De Groot

List of Publications by Year
in descending order

218 papers	6,686 citations	66343 42 h-index	85541 71 g-index
234 all docs	234 docs citations	234 times ranked	5772 citing authors

#	Article	IF	Citations
1	Neoantigen-based personalized cancer vaccines: the emergence of precision cancer immunotherapy. Expert Review of Vaccines, 2022, 21, 173-184.	4.4	17
2	Evaluation of a Human T Cell-Targeted Multi-Epitope Vaccine for Q Fever in Animal Models of Coxiella burnetii Immunity. Frontiers in Immunology, 2022, 13, .	4.8	7
3	Novel H7N9 influenza immunogen design enhances mobilization of seasonal influenza T cell memory in H3N2 pre-immune mice. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	0
4	Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses. Clinical Immunology, 2021, 224, 108661.	3.2	10
5	Self-Replicating RNAs Drive Protective Anti-tumor T Cell Responses to Neoantigen Vaccine Targets in a Combinatorial Approach. Molecular Therapy, 2021, 29, 1186-1198.	8.2	14
6	Tregitopes Improve Asthma by Promoting Highly Suppressive and Antigen-Specific Tregs. Frontiers in Immunology, 2021, 12, 634509.	4.8	12
7	Clinical outcomes of a community clinic-based lifestyle change program for prevention and management of metabolic syndrome: Results of the 'Vida Sana/Healthy Life' program. PLoS ONE, 2021, 16, e0248473.	2.5	0
8	Quantifying the Persistence of Vaccine-Related T Cell Epitopes in Circulating Swine Influenza A Strains from 2013–2017. Vaccines, 2021, 9, 468.	4.4	3
9	Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Scientific Reports, 2021, 11, 9983.	3.3	4
10	Identification, Selection and Immune Assessment of Liver Stage CD8 T Cell Epitopes From Plasmodium falciparum. Frontiers in Immunology, 2021, 12, 684116.	4.8	0
11	Highly conserved, non-human-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation. Npj Vaccines, 2021, 6, 71.	6.0	23
12	Bridging Computational Vaccinology and Vaccine Development Through Systematic Identification, Characterization, and Downselection of Conserved and Variable Circumsporozoite Protein CD4 T Cell Epitopes From Diverse Plasmodium falciparum Strains. Frontiers in Immunology, 2021, 12, 689920.	4.8	3
13	Recruitment, Training, and Roles of the Bilingual, Bicultural Navegantes: Developing a Specialized Workforce of Community Health Workers to Serve a Low-Income, Spanish-Speaking Population in Rhode Island. Frontiers in Public Health, 2021, 9, 666566.	2.7	5
14	Development of a novel fully functional coagulation factor VIII with reduced immunogenicity utilizing an in silico prediction and deimmunization approach. Journal of Thrombosis and Haemostasis, 2021, 19, 2161-2170.	3.8	8
15	Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease. Frontiers in Immunology, 2021, 12, 636731.	4.8	10
16	Identification and Immune Assessment of T Cell Epitopes in Five Plasmodium falciparum Blood Stage Antigens to Facilitate Vaccine Candidate Selection and Optimization. Frontiers in Immunology, 2021, 12, 690348.	4.8	4
17	Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases. Clinical Immunology, 2021, 233, 108888.	3.2	8
18	Immune escape and immune camouflage may reduce the efficacy of RTS,S vaccine in Malawi. Human Vaccines and Immunotherapeutics, 2020, 16, 214-227.	3.3	17

#	Article	IF	Citations
19	Differential functional patterns of memory CD4+ and CD8+ T-cells from volunteers immunized with Ty21a typhoid vaccine observed using a recombinant Escherichia coli system expressing S. Typhi proteins. Vaccine, 2020, 38, 258-270.	3.8	7
20	Exploit T cell Immunity for Rapid, Safe and Effective COVID-19 Vaccines. Expert Review of Vaccines, 2020, 19, 781-784.	4.4	1
21	Novel multiparameter correlates of Coxiella burnetii infection and vaccination identified by longitudinal deep immune profiling. Scientific Reports, 2020, 10, 13311.	3.3	10
22	Immune-engineered H7N9 influenza hemagglutinin improves protection against viral influenza virus challenge. Human Vaccines and Immunotherapeutics, 2020, 16, 2042-2050.	3.3	7
23	New Immunoinformatics Tools for Swine: Designing Epitope-Driven Vaccines, Predicting Vaccine Efficacy, and Making Vaccines on Demand. Frontiers in Immunology, 2020, 11, 563362.	4.8	9
24	European Immunogenicity Platform 11th Open Scientific Symposium on immunogenicity of biopharmaceuticals. Bioanalysis, 2020, 12, 1043-1048.	1.5	1
25	T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation–Updated Consensus and Review 2020. Frontiers in Immunology, 2020, 11, 1301.	4.8	68
26	In silico identification and modification of T cell epitopes in pertussis antigens associated with tolerance. Human Vaccines and Immunotherapeutics, 2020, 16, 277-285.	3.3	16
27	T cell epitope content comparison (EpiCC) analysis demonstrates a bivalent PCV2 vaccine has greater T cell epitope overlap with field strains than monovalent PCV2 vaccines. Veterinary Immunology and Immunopathology, 2020, 223, 110034.	1.2	18
28	Better Epitope Discovery, Precision Immune Engineering, and Accelerated Vaccine Design Using Immunoinformatics Tools. Frontiers in Immunology, 2020, 11, 442.	4.8	78
29	Quantifying quality of care at a PA student-led free diabetes clinic. JAAPA: Official Journal of the American Academy of Physician Assistants, 2020, 33, 1-1.	0.3	0
30	Coxiella burnetii Epitope-Specific T-Cell Responses in Patients with Chronic Q Fever. Infection and Immunity, 2019, 87, .	2.2	10
31	Multi-antigen Vaccination With Simultaneous Engagement of the OX40 Receptor Delays Malignant Mesothelioma Growth and Increases Survival in Animal Models. Frontiers in Oncology, 2019, 9, 720.	2.8	7
32	Highly conserved influenza T cell epitopes induce broadly protective immunity. Vaccine, 2019, 37, 5371-5381.	3.8	39
33	Therapeutic administration of Tregitope-Human Albumin Fusion with Insulin Peptides to promote Antigen-Specific Adaptive Tolerance Induction. Scientific Reports, 2019, 9, 16103.	3.3	20
34	Four Years of CHEER: Cost and QALY Savings of a Free Nurse-run Walk-in Clinic Serving an Uninsured, Predominantly Spanish-speaking Immigrant Population in Providence. Journal of Health Care for the Poor and Underserved, 2019, 30, 806-819.	0.8	1
35	A prime-boost concept using a T-cell epitope-driven DNA vaccine followed by a whole virus vaccine effectively protected pigs in the pandemic H1N1 pig challenge model. Vaccine, 2019, 37, 4302-4309.	3.8	14
36	Promiscuous Coxiella burnetii CD4 Epitope Clusters Associated With Human Recall Responses Are Candidates for a Novel T-Cell Targeted Multi-Epitope Q Fever Vaccine. Frontiers in Immunology, 2019, 10, 207.	4.8	33

#	Article	IF	Citations
37	Design of a multiepitopic Zaire ebolavirus protein and its expression in plant cells. Journal of Biotechnology, 2019, 295, 41-48.	3.8	10
38	HLA- and genotype-based risk assessment model to identify infantile onset pompe disease patients at high-risk of developing significant anti-drug antibodies (ADA). Clinical Immunology, 2019, 200, 66-70.	3.2	15
39	Coagulation Factor VIII with Reduced Immunogenicity via a Direct De-immunization Approach. , 2019, 39, .		0
40	Abstract B089: Application of precision cancer immunotherapy design tools to bladder cancer: Non-self-like neoepitopes as a prognostic biomarker. , 2019, , .		0
41	Abstract 943: Filtering out self-like neoantigens improves immune response to cancer vaccines. Cancer Research, 2019, 79, 943-943.	0.9	2
42	Abstract 943: Filtering out self-like neoantigens improves immune response to cancer vaccines. , 2019, , .		0
43	Community-based childhood obesity prevention intervention for parents improves health behaviors and food parenting practices among Hispanic, low-income parents. BMC Obesity, 2018, 5, 11.	3.1	22
44	Mass spectrometry-assisted identification of ADAMTS13-derived peptides presented on HLA-DR and HLA-DQ. Haematologica, 2018, 103, 1083-1092.	3.5	17
45	Community clinic-based lifestyle change for prevention of metabolic syndrome: Rationale, design and methods of the 'Vida Sana/healthy life' program. Contemporary Clinical Trials Communications, 2018, 12, 123-128.	1.1	3
46	T cell epitope engineering: an avian H7N9 influenza vaccine strategy for pandemic preparedness and response. Human Vaccines and Immunotherapeutics, 2018, 14, 2203-2207.	3.3	10
47	De-immun ized and F unctional T herapeutic (DeFT) versions of a long lasting recombinant alpha interferon for antiviral therapy. Clinical Immunology, 2017, 176, 31-41.	3.2	19
48	A humanized mouse model identifies key amino acids for low immunogenicity of H7N9 vaccines. Scientific Reports, 2017, 7, 1283.	3.3	35
49	An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice. Human Vaccines and Immunotherapeutics, 2017, 13, 2824-2836.	3.3	21
50	T‐cell epitope content comparison (Epi<scp>CC</scp>) of swine H1 influenza A virus hemagglutinin. Influenza and Other Respiratory Viruses, 2017, 11, 531-542.	3.4	15
51	Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali. PLoS ONE, 2017, 12, e0172661.	2.5	11
52	Knowledge, attitudes, practices and willingness to vaccinate in preparation for the introduction of HPV vaccines in Bamako, Mali. PLoS ONE, 2017, 12, e0171631.	2.5	27
53	In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model. PLoS ONE, 2016, 11, e0159237.	2.5	31
54	Agility in adversity: Vaccines on Demand. Expert Review of Vaccines, 2016, 15, 1087-1091.	4.4	6

#	Article	IF	Citations
55	3 Immunogenicity of H. pylori's CagA-Derived Peptides for Future Vaccine Development. Gastroenterology, 2016, 150, S1.	1.3	0
56	T cell epitope redundancy: cross-conservation of the TCR face between pathogens and self and its implications for vaccines and autoimmunity. Expert Review of Vaccines, 2016, 15, 607-617.	4.4	28
57	Development and validation of an epitope prediction tool for swine (PigMatrix) based on the pocket profile method. BMC Bioinformatics, 2015, 16, 290.	2.6	16
58	Hit-and-run, hit-and-stay, and commensal bacteria present different peptide content when viewed from the perspective of the T cell. Vaccine, 2015, 33, 6922-6929.	3.8	6
59	Novel Methods for Addressing Immunogenicity of Therapeutic Enzymes. AAPS Advances in the Pharmaceutical Sciences Series, 2015, , 63-77.	0.6	2
60	Aspartate-Î²-hydroxylase induces epitope-specific T cell responses in hepatocellular carcinoma. Vaccine, 2015, 33, 1256-1266.	3.8	23
61	C3d adjuvant effects are mediated through the activation of C3dâ€specific autoreactive T cells. Immunology and Cell Biology, 2015, 93, 189-197.	2.3	21
62	Vida Sana: A Lifestyle Intervention for Uninsured, Predominantly Spanish-Speaking Immigrants Improves Metabolic Syndrome Indicators. Journal of Community Health, 2015, 40, 116-123.	3.8	18
63	An immunoinformatic approach for identification of Trypanosoma cruzi HLA-A2-restricted CD8+T cell epitopes. Human Vaccines and Immunotherapeutics, 2015, 11, 2322-2328.	3.3	12
64	H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance. Human Vaccines and Immunotherapeutics, 2015, 11, 2241-2252.	3.3	40
65	iVAX: An integrated toolkit for the selection and optimization of antigens and the design of epitope-driven vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 2312-2321.	3.3	83
66	Su1829 BIoinformatic Approach to Mapping Global H. pylori cagA Sequences for Targeted Vaccine Development. Gastroenterology, 2015, 148, S-528.	1.3	0
67	Time for T? Immunoinformatics addresses vaccine design for neglected tropical and emerging infectious diseases. Expert Review of Vaccines, 2015, 14, 21-35.	4.4	35
68	Preclinical development of HIvax: Human survivin highly immunogenic vaccines. Human Vaccines and Immunotherapeutics, 2015, 11, 1585-1595.	3.3	14
69	HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients. Journal of Hepatology, 2015, 62, 48-55.	3.7	39
70	Dendritic Cell-Mediated, DNA-Based Vaccination against Hepatitis C Induces the Multi-Epitope-Specific Response of Humanized, HLA Transgenic Mice. PLoS ONE, 2014, 9, e104606.	2.5	12
71	Cross-conservation of T-cell epitopes. Human Vaccines and Immunotherapeutics, 2014, 10, 256-262.	3.3	22
72	Identification and retrospective validation of T-cell epitopes in the hepatitis C virus genotype 4 proteome. Human Vaccines and Immunotherapeutics, 2014, 10, 2366-2377.	3.3	7

#	Article	IF	Citations
73	VaxCelerate II: Rapid development of a self-assembling vaccine for Lassa fever. Human Vaccines and Immunotherapeutics, 2014, 10, 3022-3038.	3.3	23
74	Smarter vaccine design will circumvent regulatory T cell-mediated evasion in chronic HIV and HCV infection. Frontiers in Microbiology, 2014, 5, 502.	3.5	13
75	Partial pathogen protection by tick-bite sensitization and epitope recognition in peptide-immunized HLA DR3 transgenic mice. Human Vaccines and Immunotherapeutics, 2014, 10, 3048-3059.	3.3	6
76	Tregitope: Immunomodulation Powerhouse. Human Immunology, 2014, 75, 1139-1146.	2.4	41
77	Immune camouflage: Relevance to vaccines and human immunology. Human Vaccines and Immunotherapeutics, 2014, 10, 3570-3575.	3.3	39
78	CHOPPI: A web tool for the analysis of immunogenicity risk from host cell proteins in CHOâ€based protein production. Biotechnology and Bioengineering, 2014, 111, 2170-2182.	3.3	47
79	ICoVax 2013: The 3rd ISV Pre-conference Computational Vaccinology Workshop. BMC Bioinformatics, 2014, 15, I1.	2.6	2
80	Integrated assessment of predicted MHC binding and cross-conservation with self reveals patterns of viral camouflage. BMC Bioinformatics, 2014, 15, S1.	2.6	34
81	Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naÃ¯ve human T cells. Vaccine, 2014, 32, 3285-3292.	3.8	21
82	Human Immune Responses to H. pylori HLA Class II Epitopes Identified by Immunoinformatic Methods. PLoS ONE, 2014, 9, e94974.	2.5	16
83	HPV knowledge and vaccine acceptance in an uninsured Hispanic population in Providence, RI. Rhode Island Medical Journal (2013), 2014, 97, 35-9.	0.2	7
84	A Nurse-Run Walk-In Clinic: Cost-Effective Alternative to Non-urgent Emergency Department Use by the Uninsured. Journal of Community Health, 2013, 38, 1042-1049.	3.8	12
85	Computational vaccinology and the ICoVax 2012 workshop. BMC Bioinformatics, 2013, 14, I1.	2.6	10
86	Regulatory T cell epitopes (Tregitopes) in IgG induce tolerance in vivo and lack immunogenicity per se. Journal of Leukocyte Biology, 2013, 94, 377-383.	3.3	31
87	Elevated antigen-specific Th2 type response is associated with the poor prognosis of hand, foot and mouth disease. Virus Research, 2013, 177, 62-65.	2.2	16
88	Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Molecular Therapy, 2013, 21, 1727-1737.	8.2	38
89	T-cell dependent immunogenicity of protein therapeutics: Preclinical assessment and mitigation. Clinical Immunology, 2013, 149, 534-555.	3.2	216
90	Tregitope update: Mechanism of action parallels IVIg. Autoimmunity Reviews, 2013, 12, 436-443.	5.8	70

#	Article	IF	Citations
91	Do Tregitopes have the potential to impact the current treatment landscape of autoimmune diseases?. Expert Review of Clinical Immunology, 2013, 9, 1155-1157.	3.0	6
92	In Vitro and In Vivo Studies of IgG-derived Treg Epitopes (Tregitopes): A Promising New Tool for Tolerance Induction and Treatment of Autoimmunity. Journal of Clinical Immunology, 2013, 33, 43-49.	3.8	61
93	Beyond humanization and de-immunization: tolerization as a method for reducing the immunogenicity of biologics. Expert Review of Clinical Pharmacology, 2013, 6, 651-662.	3.1	31
94	Epitope Recognition in HLA-DR3 Transgenic Mice Immunized to TSH-R Protein or Peptides. Endocrinology, 2013, 154, 2234-2243.	2.8	10
95	Making vaccines â€œon demandâ€• Human Vaccines and Immunotherapeutics, 2013, 9, 1877-1884.	3.3	19
96	Application of IgG-Derived Natural Treg Epitopes (IgG Tregitopes) to Antigen-Specific Tolerance Induction in a Murine Model of Type 1 Diabetes. Journal of Diabetes Research, 2013, 2013, 1-17.	2.3	37
97	Immunization with cross-conserved H1N1 influenza CD4+T-cell epitopes lowers viral burden in HLA DR3 transgenic mice. Human Vaccines and Immunotherapeutics, 2013, 9, 2060-2068.	3.3	24
98	Low immunogenicity predicted for emerging avian-origin H7N9. Human Vaccines and Immunotherapeutics, 2013, 9, 950-956.	3.3	78
99	Universal H1N1 influenza vaccine development. Human Vaccines and Immunotherapeutics, 2013, 9, 1598-1607.	3.3	23
100	The two-faced T cell epitope. Human Vaccines and Immunotherapeutics, 2013, 9, 1577-1586.	3.3	88
101	Tregitope Peptides: The Active Pharmaceutical Ingredient of IVIG?. Clinical and Developmental Immunology, 2013, 2013, 1-6.	3.3	17
102	A Cross-Sectional Study to Assess HPV Knowledge and HPV Vaccine Acceptability in Mali. PLoS ONE, 2013, 8, e56402.	2.5	52
103	Adherence to American Diabetes Association guidelines in a volunteer-run free clinic for the uninsured: better than standards achieved by clinics for insured patients. Rhode Island Medical Journal (2013), 2013, 96, 25-9.	0.2	6
104	Moving *Helicobacter pylori* vaccine development forward with bioinformatics and immunomics. Expert Review of Vaccines, 2012, 11, 1031-1033.	4.4	9
105	Immunogenicity and immune modulatory effects of in silico predicted *L. donovani* candidate peptide vaccines. Human Vaccines and Immunotherapeutics, 2012, 8, 1769-1774.	3.3	33
106	Fifth Vaccine Renaissance introduction. Human Vaccines and Immunotherapeutics, 2012, 8, 960-960.	3.3	0
107	Immunoinformatic analysis of Chinese hamster ovary (CHO) protein contaminants in therapeutic protein formulations. , 2012, , .		0
108	Report from the field. Human Vaccines and Immunotherapeutics, 2012, 8, 1006-1009.	3.3	2

#	ARTICLE	IF	CITATIONS
109	New vaccines needed for pathogens infecting animals and humans. Human Vaccines and Immunotherapeutics, 2012, 8, 971-978.	3.3	12
110	Further progress on defining highly conserved immunogenic epitopes for a global HIV vaccine: HLA-A3-restricted GAIA vaccine epitopes. Human Vaccines and Immunotherapeutics, 2012, 8, 987-1000.	3.3	13
111	Of [hamsters] and men. Human Vaccines and Immunotherapeutics, 2012, 8, 1172-1174.	3.3	36
112	Teaching tolerance. Human Vaccines and Immunotherapeutics, 2012, 8, 1459-1464.	3.3	17
113	Conservation of HIV-1 T cell epitopes across time and clades: Validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Vaccine, 2012, 30, 7547-7560.	3.8	13
114	Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine. Retrovirology, 2012, 9, .	2.0	0
115	Knowledge/attitude/practices of HPV & cervical cancer, willingness to participate in vaccine trial in preparation for HIV & HPV vaccine trials in Mali. Retrovirology, 2012, 9, .	2.0	2
116	HIV-free children born to HIV-seropositive mothers in Bamako, Mali: a six-year perspective on providing MTCTP at the front line of AIDS. Retrovirology, 2012, 9, P212.	2.0	0
117	Conservation of HIV-1 T cell epitopes across time and clades: validation of immunogenic HLA-A2 epitopes selected for the GAIA HIV vaccine. Retrovirology, 2012, 9, .	2.0	0
118	Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World Journal of Gastroenterology, 2012, 18, 4288.	3.3	18
119	Effect of HLA DR epitope de-immunization of Factor VIII in vitro and in vivo. Clinical Immunology, 2012, 142, 320-331.	3.2	68
120	A Dominant EV71-Specific CD4+ T Cell Epitope Is Highly Conserved among Human Enteroviruses. PLoS ONE, 2012, 7, e51957.	2.5	15
121	HIV-1 Vaccine Trials: Evolving Concepts and Designs. Open AIDS Journal, 2012, 6, 274-288.	0.5	20
122	Reducing Protein Immunogenicity by Design: Deimmunization and Tolerance Induction. , 2012, , 525-534.		0
123	VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine, 2011, 29, 501-511.	3.8	49
124	HelicoVax: Epitope-based therapeutic Helicobacter pylori vaccination in a mouse model. Vaccine, 2011, 29, 2085-2091.	3.8	64
125	Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4+ T cells against the swine-origin H1N1 influenza virus. Vaccine, 2011, 29, 3299-3309.	3.8	51
126	Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis. Neurology Research International, 2011, 2011, 1-6.	1.3	23

#	ARTICLE	IF	CITATIONS
127	A comparison of two methods for T cell epitope mapping: ?cell free? in vitro versus immunoinformatics. Immunome Research, 2011, 7, .	0.1	10
128	Harnessing the power of genomics and immunoinformatics to produce improved vaccines. Expert Opinion on Drug Discovery, 2011, 6, 9-15.	5.0	12
129	Immunoinformatic discovery of potential cross-reactive T cell epitopes in the measles genome. , 2011, , .		0
130	Immunogenic Consensus Sequence T helper Epitopes for a Pan-Burkholderia Biodefense Vaccine. Immunome Research, 2011, 7, .	0.1	14
131	An Integrated Genomic and Immunoinformatic Approach to H. pylori Vaccine Design. Immunome Research, 2011, 7, .	0.1	7
132	Can we prevent immunogenicity of human protein drugs?. Annals of the Rheumatic Diseases, 2010, 69, i72-i76.	0.9	38
133	Emerging Vaccine Informatics. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-26.	3.0	114
134	Vaccine Informatics. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-2.	3.0	5
135	A Method for Individualizing the Prediction of Immunogenicity of Protein Vaccines and Biologic Therapeutics: Individualized T Cell Epitope Measure (iTEM). Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	30
136	Time for T? Thoughts about the 2009 novel H1N1 influenza outbreak and the role of T cell epitopes in the next generation of influenza vaccines. Hum Vaccin, 2010, 6, 157-163.	2.4	3
137	Species neutral correlates of immunogenicity for vaccines and protein therapeutics: Fact or Science Fiction. Hum Vaccin, 2010, 6, 368-372.	2.4	4
138	The Role of Glutamic or Aspartic Acid in Position Four of the Epitope Binding Motif and Thyrotropin Receptor-Extracellular Domain Epitope Selection in Graves' Disease. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2909-2916.	3.6	18
139	Immunoinformatic-drivenH. pylorivaccine design. , 2010, , .		0
140	Immunoinformatic approach to a multi-pathogen genome-derived epitope-driven vaccine. , 2010, , .		0
141	Use of Bioinformatics to Predict MHC Ligands and T-Cell Epitopes. Methods in Microbiology, 2010, 37, 35-66.	0.8	5
142	Immunoinformatics: The Next Step in Vaccine Design. , 2010, , 223-244.		2
143	Species neutral correlates of immunogenicity for vaccines and protein therapeutics: fact or science fiction. Hum Vaccin, 2010, 6, 371-2.	2.4	0
144	Exploring the immunome: A brave new world for human vaccine development. Hum Vaccin, 2009, 5, 790-793.	2.4	4

#	ARTICLE	IF	CITATIONS
145	Reducing risk, improving outcomes: Bioengineering less immunogenic protein therapeutics. Clinical Immunology, 2009, 131, 189-201.	3.2	165
146	T cell epitope: Friend or Foe? Immunogenicity of biologics in contextâ˜†. Advanced Drug Delivery Reviews, 2009, 61, 965-976.	13.7	90
147	In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. Vaccine, 2009, 27, 6471-6479.	3.8	58
148	Epitope-based vaccination against pneumonic tularemia. Vaccine, 2009, 27, 5299-5306.	3.8	36
149	Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008â€"2009 conventional influenza vaccine. Vaccine, 2009, 27, 5740-5747.	3.8	86
150	Immunome-derived Epitope-driven Vaccines (ID-EDV) Protect against Viral or Bacterial Challenge in Humanized Mice. Procedia in Vaccinology, 2009, 1, 15-22.	0.4	2
151	A Novel Compound for the Treatment of Allergy and Autoimmune Diseases. Journal of Allergy and Clinical Immunology, 2009, 123, S139-S139.	2.9	0
152	Mycobacterium tuberculosis. , 2009, , 1219-1239.		1
153	P17-26. Effective design of T-cell driven vaccines applied to the GAIA HIV vaccine: advances in vaccine design based on current preclinical success. Retrovirology, 2009, 6, .	2.0	0
154	P15-07. Knowledge, attitudes, practices and willingness to participate in HIV vaccine trials among urban residents of Bamako, Mali, in West Africa, 2005â€"2009. Retrovirology, 2009, 6, .	2.0	1
155	Epitope-Based Immunome-Derived Vaccines: A Strategy for Improved Design and Safety. , 2009, , 39-69.		36
156	Suppression of CTL Responses against AAV-Capsid Epitopes by Peptide-Induced Regulatory T Cells.. Blood, 2009, 114, 377-377.	1.4	4
157	Novel function of complement C3d as an autologous helper Tâ€‹cell target. Immunology and Cell Biology, 2008, 86, 221-225.	2.3	21
158	Nucleophosmin leukaemic mutants contain C-terminus peptides that bind HLA class I molecules. Leukemia, 2008, 22, 424-426.	7.2	25
159	Immunoinformatics Applied to Modifying and Improving Biological Therapeutics. , 2008, , 109-131.		1
160	Identification of immunogenic HLA-B7 â€œAchillesâ€™ heelâ€•epitopes within highly conserved regions of HIV. Vaccine, 2008, 26, 3059-3071.	3.8	42
161	The measles campaign in West and Central Africa: Remembering the future. Vaccine, 2008, 26, 3783-3786.	3.8	2
162	Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates. Current Opinion in Pharmacology, 2008, 8, 620-626.	3.5	96

#	Article	IF	Citations
163	A call to cellular & humoral arms: Enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A. Hum Vaccin, 2008, 4, 148-157.	2.4	42
164	Identification of genome-derived vaccine candidates conserved between human and mouse-adapted strains ofH. pylori. Hum Vaccin, 2008, 4, 219-223.	2.4	16
165	Activation of natural regulatory T cells by IgG Fcâ€"derived peptide â€œTregitopesâ€. Blood, 2008, 112, 3303-3311.	1.4	350
166	From Immunome to Vaccine: Epitope Mapping and Vaccine Design Tools. Novartis Foundation Symposium, 2008, , 57-76.	1.1	21
167	De-Immunization of Human Factor VIII: Identification of Epitopes in the C2 Domain. Blood, 2008, 112, 1030-1030.	1.4	0
168	IgG-Derived Tregitope Peptides Suppress T Cell Responses in Vitro and in Vivo. Blood, 2008, 112, 677-677.	1.4	0
169	Epitope-Driven TB Vaccine Development: A Streamlined Approach Using Immuno-Informatics, ELISpot Assays, and HLA Transgenic Mice. Current Molecular Medicine, 2007, 7, 351-363.	1.3	47
170	Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: Identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. Vaccine, 2007, 25, 3179-3191.	3.8	65
171	Analysis of ChimeriVax Japanese Encephalitis Virus envelope for T-cell epitopes and comparison to circulating strain sequences. Vaccine, 2007, 25, 8077-8084.	3.8	6
172	Immunogenicity of protein therapeutics. Trends in Immunology, 2007, 28, 482-490.	6.8	438
173	New tools, new approaches and new ideas for vaccine development. Expert Review of Vaccines, 2007, 6, 125-127.	4.4	17
174	Clinical validation of the â€œin silicoâ€ prediction of immunogenicity of a human recombinant therapeutic protein. Clinical Immunology, 2007, 124, 26-32.	3.2	135
175	Prediction of immunogenicity for therapeutic proteins: state of the art. Current Opinion in Drug Discovery & Development, 2007, 10, 332-40.	1.9	42
176	Tularemia vaccines - an overview. Medicine and Health, Rhode Island, 2007, 90, 311-4.	0.1	7
177	Efficacy of novel plasmid DNA encoding vaccinia antigens in improving current smallpox vaccination strategy. Vaccine, 2006, 24, 4461-4470.	3.8	19
178	Putting immunoinformatics to the test. Nature Biotechnology, 2006, 24, 791-792.	17.5	19
179	Evolutionary deimmunization: An ancillary mechanism for self-tolerance?. Cellular Immunology, 2006, 244, 148-153.	3.0	27
180	Immunomics: discovering new targets for vaccines and therapeutics. Drug Discovery Today, 2006, 11, 203-209.	6.4	147

#	Article	IF	Citations
181	Confirmation of Immunogenic Consensus Sequence HIV-1 T-cell Epitopes in Bamako, Mali and Providence, Rhode Island. Hum Vaccin, 2006, 2, 119-128.	2.4	31
182	Thyrotropin Receptor Epitopes and Their Relation to Histocompatibility Leukocyte Antigen-DR Molecules in Graves'â€™ Disease. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2286-2294.	3.6	43
183	Challenges and opportunities for HIV care in jails and prisons in the United States. International Journal of Prisoner Health, 2006, 2, 173-191.	0.9	3
184	Analyzing Mycobacterium tuberculosis proteomes for candidate vaccine epitopes. Tuberculosis, 2005, 85, 95-105.	1.9	79
185	Developing an epitope-driven tuberculosis (TB) vaccine. Vaccine, 2005, 23, 2121-2131.	3.8	76
186	HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine, 2005, 23, 2136-2148.	3.8	76
187	HLA-A2-Restricted CD8 + -Cytotoxic-T-Cell Responses to Novel Epitopes in Mycobacterium tuberculosis Superoxide Dismutase, Alanine Dehydrogenase, and Glutamine Synthetase. Infection and Immunity, 2004, 72, 2412-2415.	2.2	52
188	Genome-derived vaccines. Expert Review of Vaccines, 2004, 3, 59-76.	4.4	74
189	Immunome-derived vaccines. Expert Opinion on Biological Therapy, 2004, 4, 767-772.	3.1	24
190	Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods, 2004, 34, 476-487.	3.8	42
191	From genome to vaccineâ€"new immunoinformatics tools for vaccine design. Methods, 2004, 34, 425-428.	3.8	79
192	T cell epitope identification for bovine vaccines: an epitope mapping method for BoLA A-11. International Journal for Parasitology, 2003, 33, 641-653.	3.1	14
193	Mapping cross-clade HIV-1 vaccine epitopes using a bioinformatics approach. Vaccine, 2003, 21, 4486-4504.	3.8	68
194	How the SARS vaccine effort can learn from HIV?speeding towards the future, learning from the past. Vaccine, 2003, 21, 4095-4104.	3.8	35
195	Bioinformatics tools for identifying class I-restricted epitopes. Methods, 2003, 29, 289-298.	3.8	51
196	Greater CD8+ TCR Heterogeneity and Functional Flexibility in HIV-2 Compared to HIV-1 Infection. Journal of Immunology, 2003, 171, 307-316.	0.8	42
197	Modelling the immunogenicity of therapeutic proteins using T cell epitope mapping. Developments in Biologicals, 2003, 112, 71-80.	0.5	5
198	From immunome to vaccine: epitope mapping and vaccine design tools. Novartis Foundation Symposium, 2003, 254, 57-72; discussion 72-6, 98-101, 250-2.	1.1	9

#	Article	IF	Citations
199	Use of bioinformatics to predict MHC ligands and T-cell epitopes: Application to epitope-driven vaccine design. Methods in Microbiology, 2002, 32, 99-123.	0.8	1
200	Immunoâ€informatics: Mining genomes for vaccine components. Immunology and Cell Biology, 2002, 80, 255-269.	2.3	153
201	An HLA-Directed Molecular and Bioinformatics Approach Identifies New HLA-A11 HIV-1 Subtype E Cytotoxic T Lymphocyte Epitopes in HIV-1-Infected Thais. AIDS Research and Human Retroviruses, 2001, 17, 703-717.	1.1	50
202	From genome to vaccine: in silico predictions, ex vivo verification. Vaccine, 2001, 19, 4385-4395.	3.8	152
203	Rapid Determination of HLA B*07 Ligands from the West Nile Virus NY99 Genome. Emerging Infectious Diseases, 2001, 7, 706-713.	4.3	22
204	Identification of Subdominant Cytotoxic T Lymphocyte Epitopes Encoded by Autologous HIV Type 1 Sequences, Using Dendritic Cell Stimulation and Computer-Driven Algorithm. AIDS Research and Human Retroviruses, 2000, 16, 67-76.	1.1	31
205	In silico predictions; in vivo veritas. Nature Biotechnology, 1999, 17, 533-534.	17.5	14
206	Legacy of light for women living with HIV in prison. Lancet, The, 1999, 353, 1107-1108.	13.7	0
207	Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. Vaccine, 1998, 16, 1880-1884.	3.8	95
208	Co-infection with Mycobacterium tuberculosis and HIV in high risk clinical care settings in Rhode Island. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 1998, 10, 221-229.	1.2	6
209	A Standard of HIV Care for Incarcerated Women: Northeastern United Statesâ€™ Experiences. Journal of Correctional Health Care, 1998, 5, 139-177.	0.5	2
210	Introduction to the Compendium. Journal of Correctional Health Care, 1998, 5, 125-128.	0.5	1
211	Critical Prevention, Critical Care: Gynecological and Obstetrical Aspects of Comprehensive HIV Prevention and Treatment Among Incarcerated Women. Journal of Correctional Health Care, 1998, 5, 201-223.	0.5	1
212	Molecular Epidemiology of HIV-1 Infection in the Philippines, 1985 to 1997: Transmission of Subtypes B and E and Potential Emergence of Subtypes C and F. Journal of Acquired Immune Deficiency Syndromes, 1998, 18, 260-269.	0.3	22
213	An Interactive Web Site Providing Major Histocompatibility Ligand Predictions: Application to HIV Research. AIDS Research and Human Retroviruses, 1997, 13, 529-531.	1.1	98
214	Prediction of HIV Peptide Epitopes by a Novel Algorithm. AIDS Research and Human Retroviruses, 1996, 12, 593-610.	1.1	41
215	Risks for HIV Infection in Incarcerated Women. Journal of Women's Health, 1995, 4, 569-577.	0.9	14
216	Prevalence of Prior Sexual Abuse and HIV Risk-taking Behaviors in Incarcerated Women in Massachusetts. Journal of Correctional Health Care, 1995, 2, 137-149.	0.5	5

#	ARTICLE	IF	CITATIONS
217	Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. Vaccine, 1995, 13, 581-591.	3.8	148
218	Human Immunodeficiency Virus Reverse Transcriptase T Helper Epitopes Identified in Mice and Humans: Correlation with a Cytotoxic T Cell Epitope. Journal of Infectious Diseases, 1991, 164, 1058-1065.	4.0	34